World Federation of Hemophilia
-
Novo Nordisk announces FDA approves the Biologics License Application for ESPEROCT®
Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life...
-
CSL Behring today renews commitment to WFH
CSL Behring today announced that the company has renewed its commitment as a Visionary Corporate Partner with the WFH for another three years. This is...
-
Happy new year from the WFH
The World Federation of Hemophilia (WFH) wishes you, your friends, your family, and the whole global bleeding disorders community a wonderful new year. Happy 2019!
-
WFH supports MASAC’s recommendation on the risks of gene therapy trials for hemophilia
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #254, entitled, “MASAC Document Regarding Risks of Gene Therapy Trials for Hemophilia”. MASAC’s recommendation...
-
WFH Medical Advisory Board (MAB) supports MASAC’s recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors
On December 6, 2018, MASAC—the NHF’s Medical and Scientific Advisory Council—published recommendation #255 entitled, “Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia...
-
Glenn Pierce: a short bio of the new WFH Vice President, Medical
Glenn Pierce – WFH Vice President, Medical, WFH USA Board Member and Vice President Glenn Pierce, was elected to a four-year term as World Federation...
-
Glenn Pierce, VP Medical, discusses goals and challenges
Glenn Pierce, MD, PhD was elected as VP Medical for the World Federation of Hemophilia (WFH) at the WFH 2018 World Congress this past May...
-
Alert on the use of vials of water for injection (2.5ml, 5ml and 10ml) included in some LFB BIOMEDICAMENTS products
Please note that LFB BIOMEDICAMENTS has issued an alert concerning a defect in the quality appearance of the water for injection (vials 2.5ml, 5ml and...
-
First case of an anti-drug antibody reported in Hemlibra trial
Roche has reported that a young patient in the HAVEN 2 clinical trial for Hemlibra (emicizumab) has developed an anti-drug antibody to Hemlibra resulting in...
-
Update from Roche on Hemlibra (emicizumab)
Update from Roche on Hemlibra (emicizumab), for more information please click here.
